IONIS PHARMACEUTICALS INC 4

EVP and Chief Business Officer Joseph Baroldi, via his spouse, exercised 5,635 stock options and sold the resulting 5,635 Ionis Pharmaceuticals (IONS) shares at about $80.16 on June 26, 2026 under a Rule 10b5‑1 plan.

On June 26, 2026, Ionis Pharmaceuticals EVP and Chief Business Officer Joseph Baroldi, through his spouse’s account, exercised two non-qualified stock option grants (1,769 shares at a $32.60 strike and 3,866 shares at a $56.78 strike) for a total of 5,635 Ionis common shares, then sold all 5,635 shares at a weighted average price of $80.1595 under a pre‑established Rule 10b5‑1 trading plan, resulting in a net increase in his spouse’s indirect common stock holdings to 4,669 shares and leaving Baroldi with 48,522 shares held directly. The option exercises were reported as cashless (price per share of $0.0 in the derivative exercise lines), and following the transactions, the indirect holdings (by spouse) are reported at 10,304 shares for the acquisition-side ledger and 4,669 shares for the post-sale ledger, while his directly held position is disclosed as 48,522 common shares, with the aggregate values inferred from the sale and exercise prices.

Filing Facts

CIK

874015

Ticker

IONS

Form

4

Source Type

sec

Accession

0000874015-26-000218

Alert Tier

6